Clinical Trial Update: A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 trial assessing relative bioavailability and food effects of a fixed-dose combination of GSK3640254 and dolutegravir in healthy participants has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dolutegravir (dolutegravir)
• GSK3640254

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2024-03-12